文献速递瓣膜病与结构性心脏病肺血管病与心包/心肌炎

西地那非对已矫正瓣膜病合并持续性肺动脉高压患者结局的影响:多中心双盲随机临床试验

Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
PubMed 文献 · Eur Heart J · 2018-01-01

SIOVAC研究为多中心、随机、双盲、安慰剂对照试验,纳入200例瓣膜置换或修复术后至少1年、平均肺动脉压≥30 mmHg的稳定成人患者,随机接受西地那非40 mg每日三次(n=104)或安慰剂(n=96)治疗6个月。主要复合临床评分显示西地那非组仅27例改善而安慰剂组44例改善,西地那非组33例恶化而安慰剂组14例恶化(OR 0.39,95%CI 0.22-0.67,P<0.001),西地那非组无心力衰竭住院生存率更低(HR 2.0,95%CI 1.0-4.0,log-rank P=0.044)。结论认为已成功矫正瓣膜病后持续性肺动脉高压患者使用西地那非与更差临床结局相关,应避免超说明书使用。

要点

  • 西地那非组复合临床评分恶化比例高于安慰剂组(33例 vs 14例)。
  • 西地那非组无心衰住院生存率低于安慰剂组(HR 2.0,95%CI 1.0-4.0)。
  • 已矫正瓣膜病后持续性肺动脉高压患者应避免超说明书使用西地那非。

核心结论

  • 已成功矫正瓣膜病后持续性肺动脉高压患者使用西地那非与比安慰剂更差的临床结局相关。
  • 应避免超说明书使用西地那非治疗此类左心疾病相关肺动脉高压。

研究设计与样本

  • SIOVAC研究为多中心、随机、平行、安慰剂对照试验,纳入200例患者。
  • 纳入标准为瓣膜置换或修复术后至少1年、平均肺动脉压≥30 mmHg的稳定成人。
  • 患者随机接受西地那非40 mg每日三次(n=104)或安慰剂(n=96)治疗6个月。

主要发现

  • 西地那非组27例复合临床评分改善,安慰剂组44例改善;西地那非组33例恶化,安慰剂组14例恶化(OR 0.39,95%CI 0.22-0.67,P<0.001)。
  • 无心力衰竭住院生存的Kaplan-Meier估计值在西地那非组和安慰剂组分别为0.76和0.86(HR 2.0,95%CI 1.0-4.0,log-rank P=0.044)。
  • 两组6分钟步行试验距离、利钠肽和Doppler估测收缩期肺动脉压力的变化相似。

关键数值与推荐

  • 主要终点为结合死亡、心力衰竭住院、功能分级变化和患者整体自评的复合临床评分。
  • 西地那非用法为40 mg每日三次,治疗6个月。

临床怎么用

  • 对于已成功矫正瓣膜病后持续性肺动脉高压患者,不应超说明书使用西地那非。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We aimed to determine whether treatment with sildenafil improves outcomes of patients with persistent pulmonary hypertension (PH) after correction of valvular heart disease (VHD). METHODS AND RESULTS: The sildenafil for improving outcomes after valvular correction (SIOVAC) study was a multricentric, randomized, parallel, and placebo-controlled trial that enrolled stable adults with mean pulmonary artery pressure ≥ 30 mmHg who had undergone a successful valve replacement or repair procedure at least 1 year before inclusion. We assigned 200 patients to receive sildenafil (40 mg three times daily, n = 104) or placebo (n = 96) for 6 months. The primary endpoint was the composite clinical score combining death, hospital admission for heart failure (HF), change in functional class, and patient global self-assessment. Only 27 patients receiving sildenafil improved their composite clinical score, as compared with 44 patients receiving placebo; in contrast 33 patients in the sildenafil group worsened their composite score, as compared with 14 in the placebo group [odds ratio 0.39; 95% confidence interval (CI) 0.22-0.67; P < 0.001]. The Kaplan-Meier estimates for survival without admission due to HF were 0.76 and 0.86 in the sildenafil and placebo groups, respectively (hazard ratio 2.0, 95% CI = 1.0-4.0; log-rank P = 0.044). Changes in 6-min walk test distance, natriuretic peptides, and Doppler-derived systolic pulmonary pressure were similar in both groups. CONCLUSION: Treatment with sildenafil in patients with persistent PH after successfully corrected VHD is associated to worse clinical outcomes than placebo. Off-label usage of sildenafil for treating this source of left heart disease PH should be avoided. The trial is registered with ClinicalTrials.gov, number NCT00862043.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Bermejo J, Yotti R, García-Orta R, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018. PMID: 29281101. doi:10.1093/eurheartj/ehx700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。